References
- Fu AZ, Qiu Y, Radican L, et al. Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe: a matched study. Diabetes Obes Metab 2010;12:631-7
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
- Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82
- Fu AZ, Qiu Y, Radican L, Luo N. Marginal differences in health-related quality of life of diabetic patients with and without macrovascular comorbid conditions in the United States. Qual Life Res 2011;20:825-32
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438-47
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
- McCoy RG, Zhang Y, Herrin J, et al. Changing trends in type 2 diabetes mellitus treatment intensification, 2002–2010. Am J Manag Care 2015;21:e288-96
- Lin J, Zhou S, Wei W, et al. Does clinical inertia vary by personalized a1c goal? A study of predictors and prevalence of clinical inertia in a U.S. managed-care setting. Endocr Pract 2016;22:151-61
- Fu AZ, Qiu Y, Davies MJ, et al. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011;13:765-9
- Fu AZ, Sheehan J. Treatment intensification for patients with type 2 diabetes and poor glycemic control. Diabetes Obes Metab 2016;18:892-8
- Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100
- Fu AZ, Qiu Y, Radican L, et al. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study. Cardiovasc Diabetol 2010;9:15
- Hansen LG, Chang S. Health Research Data for the Real World: The MarketScan Databases. White paper. 2011 http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf
- Quint JB. Health Research Data for the Real World: The MarketScan Databases. White paper. Truven Health Analytics, 2015 http://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases
- National Quality Forum. Adding Value to Diabetes Quality Measures: Opportunities and Methodological Challenges. National Quality Forum 2015 http://www.qualityforum.org/Publications/2008/11/White_Paper,_Adding_Value_to_Diabetes_Quality_Measures__Opportunities_and_Methodological_Challenges.aspx
- Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. SAS Users Group International (SUGI) 26th conference. Paper 214–26. 2001
- Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34
- Romanelli RJ, Chung S, Pu J, et al. Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2015;108:170-8
- Rajpathak SN, Rajgopalan S, Engel SS. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications 2014;28:831-5
- Levin PA, Wei W, Zhou S, et al. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. J Manag Care Spec Pharm 2014;20:501-12